MedTrop 2019

Congress of the Brazilian Society of Tropical Medicine

28-31 July 2019
Belo Horizonte, Brazil

  • DNDi participating in several round tables on Chagas disease, leishmaniasis, and hepatitis C

Wellcome Centre for Anti-Infective Research at the University of Dundee

12-15 May 2019
Dundee, UK

  • Isabela Ribeiro, Head of Dynamic Portfolio Unit – presentation on clinical trials for Chagas disease
  • Nick White, Chair DNDi SAC – presentation on the global situation in infectious diseases & drug discovery for infectious diseases
  • Poster presentations on drug discovery projects for Chagas disease and leishmaniasis

R&D Portfolio Update February 2019: DNDi Leishmaniasis programme

In Africa, results of a Phase III study on HIV/VL in Ethiopia showed high efficacy of a new combination therapy for co-infected patients, a Phase III study began to test new combination treatment for visceral leishmaniasis, and a Phase II study testing new treatments for PKDL started in Sudan. In Asia, the results of an infectivity study in Bangladesh confirmed that PKDL acts as a reservoir for leishmaniasis infection, with implications for elimination efforts across South Asia. In Latin America, the Brazilian Ministry of Health is reviewing its treatment policy to consider the adoption of AmBisome as the country’s first-line visceral leishmaniasis treatment.

Wellcome commits £10 million to DNDi to develop new generation of oral drugs to treat leishmaniasis

London/Geneva – 5 February 2019
Wellcome has committed over £10 million to DNDi to develop new treatments for leishmaniasis, one of the world’s most devastating parasitic diseases. The three-year partnership will enable DNDi and Wellcome to develop new combinations of entirely new, all-orally acting chemical entities, through a joint strategy that also harnesses the strengths of the pharmaceutical and biotechnology industries, academia, and product development partnerships.

CTDDR 2019

20-23 February 2019
Lucknow, India

  • Presentation of the development of DNDI-0690, a new clinical candidate for visceral leishmaniasis

Spandan Features [29 January 2019]

“एक दशक में मिल सकती है काला अजार के उपचार की नयी थेरेपी” – “A new therapy can be developed for effective treatment of kala-azar in the next decade”

Click here to read the article